 | • レポートコード：GIR-107A12548 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、抗癌剤におけるパクリタキセル・その類似体のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。抗癌剤におけるパクリタキセル・その類似体の種類別市場規模（パクリタキセル、ドセタキセル、リポソームパクリタキセル、タンパク質結合パクリタキセル）、用途別市場規模（卵巣がん、乳がん、子宮頸がん、膵臓がん、非小細胞肺がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・抗癌剤におけるパクリタキセル・その類似体の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bristol-Myers Squibb、Celgene Corporation、Hospira、Biological E.、Taj Accura、Khandelwal Laboratories、Luye Pharma、Beijing Youcare、Beijing Union、Haiyao、Chuntch、Hengrui Medicine、Sanofi、Qilu Pharma、Shenzhen Main Luck Pharma、Jiangsu Aosaikang Pharma、CSPC Pharmaceutical、Aosaikang Pharm ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：パクリタキセル、ドセタキセル、リポソームパクリタキセル、タンパク質結合パクリタキセル ・用途別分析2016年-2026年：卵巣がん、乳がん、子宮頸がん、膵臓がん、非小細胞肺がん、その他 ・抗癌剤におけるパクリタキセル・その類似体の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・抗癌剤におけるパクリタキセル・その類似体のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・抗癌剤におけるパクリタキセル・その類似体のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・抗癌剤におけるパクリタキセル・その類似体の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・抗癌剤におけるパクリタキセル・その類似体の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Paclitaxel and Its Analogue in Anticarcinoma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Paclitaxel and Its Analogue in Anticarcinoma Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Paclitaxel and Its Analogue in Anticarcinoma Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Paclitaxel and Its Analogue in Anticarcinoma Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Paclitaxel
Docetaxel
Liposome Paclitaxel
Protein-bound Paclitaxel
Market segment by Application, can be divided into
Ovarian Cancer
Breast Cancer
Cervical Cancer
Pancreatic Cancer
Non-small Cell Lung Cancer
Other
Market segment by players, this report covers
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Khandelwal Laboratories
Luye Pharma
Beijing Youcare
Beijing Union
Haiyao
Chuntch
Hengrui Medicine
Sanofi
Qilu Pharma
Shenzhen Main Luck Pharma
Jiangsu Aosaikang Pharma
CSPC Pharmaceutical
Aosaikang Pharm
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Paclitaxel and Its Analogue in Anticarcinoma Drugs
1.2 Classification of Paclitaxel and Its Analogue in Anticarcinoma Drugs by Type
1.2.1 Overview: Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Type in 2020
1.2.3 Paclitaxel
1.2.4 Docetaxel
1.2.5 Liposome Paclitaxel
1.2.6 Protein-bound Paclitaxel
1.3 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market by Application
1.3.1 Overview: Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Cervical Cancer
1.3.5 Pancreatic Cancer
1.3.6 Non-small Cell Lung Cancer
1.3.7 Other
1.4 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size & Forecast
1.5 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast by Region
1.5.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Region, (2016-2021)
1.5.3 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Drivers
1.6.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Restraints
1.6.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Trends Analysis
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.1.4 Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.2 Celgene Corporation
2.2.1 Celgene Corporation Details
2.2.2 Celgene Corporation Major Business
2.2.3 Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.2.4 Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Celgene Corporation Recent Developments and Future Plans
2.3 Hospira
2.3.1 Hospira Details
2.3.2 Hospira Major Business
2.3.3 Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.3.4 Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Hospira Recent Developments and Future Plans
2.4 Biological E.
2.4.1 Biological E. Details
2.4.2 Biological E. Major Business
2.4.3 Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.4.4 Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Biological E. Recent Developments and Future Plans
2.5 Taj Accura
2.5.1 Taj Accura Details
2.5.2 Taj Accura Major Business
2.5.3 Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.5.4 Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Taj Accura Recent Developments and Future Plans
2.6 Khandelwal Laboratories
2.6.1 Khandelwal Laboratories Details
2.6.2 Khandelwal Laboratories Major Business
2.6.3 Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.6.4 Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Khandelwal Laboratories Recent Developments and Future Plans
2.7 Luye Pharma
2.7.1 Luye Pharma Details
2.7.2 Luye Pharma Major Business
2.7.3 Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.7.4 Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Luye Pharma Recent Developments and Future Plans
2.8 Beijing Youcare
2.8.1 Beijing Youcare Details
2.8.2 Beijing Youcare Major Business
2.8.3 Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.8.4 Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Beijing Youcare Recent Developments and Future Plans
2.9 Beijing Union
2.9.1 Beijing Union Details
2.9.2 Beijing Union Major Business
2.9.3 Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.9.4 Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Beijing Union Recent Developments and Future Plans
2.10 Haiyao
2.10.1 Haiyao Details
2.10.2 Haiyao Major Business
2.10.3 Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.10.4 Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Haiyao Recent Developments and Future Plans
2.11 Chuntch
2.11.1 Chuntch Details
2.11.2 Chuntch Major Business
2.11.3 Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.11.4 Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Chuntch Recent Developments and Future Plans
2.12 Hengrui Medicine
2.12.1 Hengrui Medicine Details
2.12.2 Hengrui Medicine Major Business
2.12.3 Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.12.4 Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Hengrui Medicine Recent Developments and Future Plans
2.13 Sanofi
2.13.1 Sanofi Details
2.13.2 Sanofi Major Business
2.13.3 Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.13.4 Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Sanofi Recent Developments and Future Plans
2.14 Qilu Pharma
2.14.1 Qilu Pharma Details
2.14.2 Qilu Pharma Major Business
2.14.3 Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.14.4 Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Qilu Pharma Recent Developments and Future Plans
2.15 Shenzhen Main Luck Pharma
2.15.1 Shenzhen Main Luck Pharma Details
2.15.2 Shenzhen Main Luck Pharma Major Business
2.15.3 Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.15.4 Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Shenzhen Main Luck Pharma Recent Developments and Future Plans
2.16 Jiangsu Aosaikang Pharma
2.16.1 Jiangsu Aosaikang Pharma Details
2.16.2 Jiangsu Aosaikang Pharma Major Business
2.16.3 Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.16.4 Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Jiangsu Aosaikang Pharma Recent Developments and Future Plans
2.17 CSPC Pharmaceutical
2.17.1 CSPC Pharmaceutical Details
2.17.2 CSPC Pharmaceutical Major Business
2.17.3 CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.17.4 CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 CSPC Pharmaceutical Recent Developments and Future Plans
2.18 Aosaikang Pharm
2.18.1 Aosaikang Pharm Details
2.18.2 Aosaikang Pharm Major Business
2.18.3 Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
2.18.4 Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Aosaikang Pharm Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Market Share
3.2.2 Top 10 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Application (2016-2021)
5.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2026)
6.2 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2026)
6.3 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country
6.3.1 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2026)
6.3.2 United States Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2026)
7.2 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2026)
7.3 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country
7.3.1 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2026)
7.3.2 Germany Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
7.3.3 France Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Region
8.3.1 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Region (2016-2026)
8.3.2 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
8.3.5 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2026)
9.2 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2026)
9.3 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country
9.3.1 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country
10.3.1 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region (2021-2026)
Table 6. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 7. Bristol-Myers Squibb Major Business
Table 8. Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 9. Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Celgene Corporation Corporate Information, Head Office, and Major Competitors
Table 11. Celgene Corporation Major Business
Table 12. Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 13. Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Hospira Corporate Information, Head Office, and Major Competitors
Table 15. Hospira Major Business
Table 16. Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 17. Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Biological E. Corporate Information, Head Office, and Major Competitors
Table 19. Biological E. Major Business
Table 20. Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 21. Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Taj Accura Corporate Information, Head Office, and Major Competitors
Table 23. Taj Accura Major Business
Table 24. Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 25. Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Khandelwal Laboratories Corporate Information, Head Office, and Major Competitors
Table 27. Khandelwal Laboratories Major Business
Table 28. Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 29. Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Luye Pharma Corporate Information, Head Office, and Major Competitors
Table 31. Luye Pharma Major Business
Table 32. Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 33. Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Beijing Youcare Corporate Information, Head Office, and Major Competitors
Table 35. Beijing Youcare Major Business
Table 36. Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 37. Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Beijing Union Corporate Information, Head Office, and Major Competitors
Table 39. Beijing Union Major Business
Table 40. Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 41. Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Haiyao Corporate Information, Head Office, and Major Competitors
Table 43. Haiyao Major Business
Table 44. Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 45. Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Chuntch Corporate Information, Head Office, and Major Competitors
Table 47. Chuntch Major Business
Table 48. Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 49. Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Hengrui Medicine Corporate Information, Head Office, and Major Competitors
Table 51. Hengrui Medicine Major Business
Table 52. Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 53. Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Sanofi Corporate Information, Head Office, and Major Competitors
Table 55. Sanofi Major Business
Table 56. Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 57. Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Qilu Pharma Corporate Information, Head Office, and Major Competitors
Table 59. Qilu Pharma Major Business
Table 60. Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 61. Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Shenzhen Main Luck Pharma Corporate Information, Head Office, and Major Competitors
Table 63. Shenzhen Main Luck Pharma Major Business
Table 64. Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 65. Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Jiangsu Aosaikang Pharma Corporate Information, Head Office, and Major Competitors
Table 67. Jiangsu Aosaikang Pharma Major Business
Table 68. Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 69. Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. CSPC Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 71. CSPC Pharmaceutical Major Business
Table 72. CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 73. CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Aosaikang Pharm Corporate Information, Head Office, and Major Competitors
Table 75. Aosaikang Pharm Major Business
Table 76. Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions
Table 77. Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) by Players (2019-2021)
Table 79. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Players (2019-2021)
Table 80. Breakdown of Paclitaxel and Its Analogue in Anticarcinoma Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 81. Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Head Office, Products and Services Provided
Table 82. Paclitaxel and Its Analogue in Anticarcinoma Drugs Mergers & Acquisitions in the Past Five Years
Table 83. Paclitaxel and Its Analogue in Anticarcinoma Drugs New Entrants and Expansion Plans
Table 84. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) by Type (2016-2021)
Table 85. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Type (2016-2021)
Table 86. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Forecast by Type (2021-2026)
Table 87. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2021)
Table 88. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Forecast by Application (2021-2026)
Table 89. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 90. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 91. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 92. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 93. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 94. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 95. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 96. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 97. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 98. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 99. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 100. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 101. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 102. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 103. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 104. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 105. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Region (2016-2021) & (USD Million)
Table 106. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Region (2021-2026) & (USD Million)
Table 107. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 108. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 109. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 110. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 111. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 112. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 113. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 114. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 115. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 116. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 117. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 118. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Paclitaxel and Its Analogue in Anticarcinoma Drugs Picture
Figure 2. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Type in 2020
Figure 3. Paclitaxel
Figure 4. Docetaxel
Figure 5. Liposome Paclitaxel
Figure 6. Protein-bound Paclitaxel
Figure 7. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Application in 2020
Figure 8. Ovarian Cancer Picture
Figure 9. Breast Cancer Picture
Figure 10. Cervical Cancer Picture
Figure 11. Pancreatic Cancer Picture
Figure 12. Non-small Cell Lung Cancer Picture
Figure 13. Other Picture
Figure 14. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region (2016-2026)
Figure 17. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region in 2020
Figure 18. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Drivers
Figure 24. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Restraints
Figure 25. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Trends
Figure 26. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 27. Celgene Corporation Recent Developments and Future Plans
Figure 28. Hospira Recent Developments and Future Plans
Figure 29. Biological E. Recent Developments and Future Plans
Figure 30. Taj Accura Recent Developments and Future Plans
Figure 31. Khandelwal Laboratories Recent Developments and Future Plans
Figure 32. Luye Pharma Recent Developments and Future Plans
Figure 33. Beijing Youcare Recent Developments and Future Plans
Figure 34. Beijing Union Recent Developments and Future Plans
Figure 35. Haiyao Recent Developments and Future Plans
Figure 36. Chuntch Recent Developments and Future Plans
Figure 37. Hengrui Medicine Recent Developments and Future Plans
Figure 38. Sanofi Recent Developments and Future Plans
Figure 39. Qilu Pharma Recent Developments and Future Plans
Figure 40. Shenzhen Main Luck Pharma Recent Developments and Future Plans
Figure 41. Jiangsu Aosaikang Pharma Recent Developments and Future Plans
Figure 42. CSPC Pharmaceutical Recent Developments and Future Plans
Figure 43. Aosaikang Pharm Recent Developments and Future Plans
Figure 44. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Players in 2020
Figure 45. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 46. Global Top 3 Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share in 2020
Figure 47. Global Top 10 Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share in 2020
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 49. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Type in 2020
Figure 50. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share Forecast by Type (2021-2026)
Figure 51. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Application in 2020
Figure 52. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share Forecast by Application (2021-2026)
Figure 53. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2016-2026)
Figure 54. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2016-2026)
Figure 55. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2016-2026)
Figure 56. United States Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Canada Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Mexico Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2016-2026)
Figure 60. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2016-2026)
Figure 61. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2016-2026)
Figure 62. Germany Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. France Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. United Kingdom Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Russia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Italy Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2016-2026)
Figure 68. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2016-2026)
Figure 69. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region (2016-2026)
Figure 70. China Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South Korea Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. India Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Australia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2016-2026)
Figure 77. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2016-2026)
Figure 78. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2016-2026)
Figure 79. Brazil Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Argentina Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2016-2026)
Figure 82. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2016-2026)
Figure 83. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2016-2026)
Figure 84. Turkey Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Saudi Arabia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. UAE Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
世界のアナログチーズ市場 2021：企業別、地域別、種類・用途別 The Cheese Analogue market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, re…- 世界の乳がん用チューブリン阻害剤市場 2021：企業別、地域別、種類・用途別 The Tubulin Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- 世界の間質性膀胱炎治療薬市場 2021：企業別、地域別、種類・用途別 The Interstitial Cystitis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- 世界の神経芽細胞腫治療薬市場 2021：企業別、地域別、種類・用途別 The Neuroblastoma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…
- 世界のホジキンリンパ腫治療薬市場 2021：企業別、地域別、種類・用途別 The Hodgkin's Lymphoma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…